99 related articles for article (PubMed ID: 16309186)
1. Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155.
Ueda Y; Yamagishi T; Samata K; Hirayama N; Aozuka Y; Tanaka M; Nakaike S; Saiki I
Anticancer Res; 2005; 25(6B):3973-7. PubMed ID: 16309186
[TBL] [Abstract][Full Text] [Related]
2. VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo.
Ueda Y; Yamagishi T; Ikeya H; Hirayama N; Itokawa T; Aozuka Y; Samata K; Nakaike S; Tanaka M; Ono M; Saiki I
Anticancer Res; 2004; 24(5A):3009-17. PubMed ID: 15517909
[TBL] [Abstract][Full Text] [Related]
3. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
[TBL] [Abstract][Full Text] [Related]
4. A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth.
Ueda Y; Yamagishi T; Samata K; Ikeya H; Hirayama N; Okazaki T; Nishihara S; Arai K; Yamaguchi S; Shibuya M; Nakaike S; Tanaka M
Cancer Chemother Pharmacol; 2004 Jul; 54(1):16-24. PubMed ID: 15064856
[TBL] [Abstract][Full Text] [Related]
5. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1.
Starzec A; Vassy R; Martin A; Lecouvey M; Di Benedetto M; Crépin M; Perret GY
Life Sci; 2006 Nov; 79(25):2370-81. PubMed ID: 16959272
[TBL] [Abstract][Full Text] [Related]
6. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition.
Zips D; Eicheler W; Geyer P; Hessel F; Dörfler A; Thames HD; Haberey M; Baumann M
Cancer Res; 2005 Jun; 65(12):5374-9. PubMed ID: 15958586
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
8. Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C; Zieher H; Roth A; Hauser K; Lipson KE; Weber KJ; Debus J; Abdollahi A; Huber PE
Clin Cancer Res; 2008 Apr; 14(7):2210-9. PubMed ID: 18381963
[TBL] [Abstract][Full Text] [Related]
9. Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
Wu Y; Zhong Z; Huber J; Bassi R; Finnerty B; Corcoran E; Li H; Navarro E; Balderes P; Jimenez X; Koo H; Mangalampalli VR; Ludwig DL; Tonra JR; Hicklin DJ
Clin Cancer Res; 2006 Nov; 12(21):6573-84. PubMed ID: 17085673
[TBL] [Abstract][Full Text] [Related]
10. Ganoderma tsugae extract inhibits expression of epidermal growth factor receptor and angiogenesis in human epidermoid carcinoma cells: In vitro and in vivo.
Hsu SC; Ou CC; Chuang TC; Li JW; Lee YJ; Wang V; Liu JY; Chen CS; Lin SC; Kao MC
Cancer Lett; 2009 Aug; 281(1):108-16. PubMed ID: 19332363
[TBL] [Abstract][Full Text] [Related]
11. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo.
Garvin S; Dabrosin C
Cancer Res; 2003 Dec; 63(24):8742-8. PubMed ID: 14695189
[TBL] [Abstract][Full Text] [Related]
13. A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155.
Ueda Y; Yamagishi T; Samata K; Ikeya H; Hirayama N; Takashima H; Nakaike S; Tanaka M; Saiki I
Mol Cancer Ther; 2003 Nov; 2(11):1105-11. PubMed ID: 14617783
[TBL] [Abstract][Full Text] [Related]
14. mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.
Lane HA; Wood JM; McSheehy PM; Allegrini PR; Boulay A; Brueggen J; Littlewood-Evans A; Maira SM; Martiny-Baron G; Schnell CR; Sini P; O'Reilly T
Clin Cancer Res; 2009 Mar; 15(5):1612-22. PubMed ID: 19223496
[TBL] [Abstract][Full Text] [Related]
15. Tumor angiogenesis promoted by ex vivo differentiated endothelial progenitor cells is effectively inhibited by an angiogenesis inhibitor, TK1-2.
Oh HK; Ha JM; O E; Lee BH; Lee SK; Shim BS; Hong YK; Joe YA
Cancer Res; 2007 May; 67(10):4851-9. PubMed ID: 17510415
[TBL] [Abstract][Full Text] [Related]
16. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Langer CJ; Natale RB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
[TBL] [Abstract][Full Text] [Related]
17. The retinoid X receptor-selective ligand, LGD1069, inhibits tumor-induced angiogenesis via suppression of VEGF in human non-small cell lung cancer.
Fu J; Ding Y; Huang D; Li H; Chen X
Cancer Lett; 2007 Apr; 248(1):153-63. PubMed ID: 17027148
[TBL] [Abstract][Full Text] [Related]
18. Mebendazole elicits a potent antitumor effect on human cancer cell lines both in vitro and in vivo.
Mukhopadhyay T; Sasaki J; Ramesh R; Roth JA
Clin Cancer Res; 2002 Sep; 8(9):2963-9. PubMed ID: 12231542
[TBL] [Abstract][Full Text] [Related]
19. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization.
LaMontagne K; Littlewood-Evans A; Schnell C; O'Reilly T; Wyder L; Sanchez T; Probst B; Butler J; Wood A; Liau G; Billy E; Theuer A; Hla T; Wood J
Cancer Res; 2006 Jan; 66(1):221-31. PubMed ID: 16397235
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]